Progress in the use of antisense oligonucleotides for vaccine improvement

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorUniversidad Valencia-
Autor(es): dc.creatorBatista-Duharte, Alexander [UNESP]-
Autor(es): dc.creatorSendra, Luis-
Autor(es): dc.creatorHerrero, Maria José-
Autor(es): dc.creatorTéllez-Martínez, Damiana [UNESP]-
Autor(es): dc.creatorCarlos, Iracilda Zeppone [UNESP]-
Autor(es): dc.creatorAliño, Salvador Francisco-
Data de aceite: dc.date.accessioned2022-02-22T00:29:21Z-
Data de disponibilização: dc.date.available2022-02-22T00:29:21Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-01-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3390/biom10020316-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/200086-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/200086-
Descrição: dc.descriptionAntisense oligonucleotides (ASOs) are synthetically prepared short single-stranded deoxynucleotide sequences that have been validated as therapeutic agents and as a valuable tool in molecular driving biology. ASOs can block the expression of specific target genes via complementary hybridization to mRNA. Due to their high specificity and well-known mechanism of action, there has been a growing interest in using them for improving vaccine efficacy. Several studies have shown that ASOs can improve the efficacy of vaccines either by inducing antigen modification such as enhanced expression of immunogenic molecules or by targeting certain components of the host immune system to achieve the desired immune response. However, despite their extended use, some problems such as insufficient stability and low cellular delivery have not been sufficiently resolved to achieve effective and safe ASO-based vaccines. In this review, we analyze the molecular bases and the research that has been conducted to demonstrate the potential use of ASOs in vaccines.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences Department of Clinical Analysis São Paulo State University (UNESP), Rod. Araraquara-Jaú-Km 1-
Descrição: dc.descriptionPharmacology Department Faculty of Medicine Universidad Valencia, Av. Blasco Ibáñez 15-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences Department of Clinical Analysis São Paulo State University (UNESP), Rod. Araraquara-Jaú-Km 1-
Descrição: dc.descriptionFAPESP: 2018/15187-2-
Idioma: dc.languageen-
Relação: dc.relationBiomolecules-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAdjuvants-
Palavras-chave: dc.subjectAntisense oligonucleotide-
Palavras-chave: dc.subjectCancer-
Palavras-chave: dc.subjectInfectious disease-
Palavras-chave: dc.subjectVaccines-
Título: dc.titleProgress in the use of antisense oligonucleotides for vaccine improvement-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.